Just a few days after NexImmune bumped up its credentials with the hiring of Gilead Sciences and Kite Pharma alum Robert Knight, M.D., the T-cell biotech is now gunning for an $86 million IPO.

The startup wants the cash to boost its work on immunotherapy, with its platform designed to employ the body’s own T cells to generate a potent and durable immune response that mimics natural biology.

“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases,” the Maryland biotech said in its Securities and Exchange Commission filing.

Read the full article at FierceBiotech